BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, Miwa S, Igarashi K, Higuchi T, Yonezawa H, Araki Y, Morinaga S, Saito S, Sone T, Kasahara K, Tsuchiya H. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer. Front Oncol 2022;12:871675. [DOI: 10.3389/fonc.2022.871675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Asano Y, Yamamoto N, Hayashi K, Takeuchi A, Miwa S, Igarashi K, Higuchi T, Taniguchi Y, Morinaga S, Horimoto T, Nakai M, Kadono Y, Nojima T, Tsuchiya H. Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors. Front Immunol 2022;13:980456. [DOI: 10.3389/fimmu.2022.980456] [Reference Citation Analysis]
2 Li H, Lei S, Li J, Xing P, Hao X, Xu F, Xu H, Wang Y. Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review. Front Immunol 2022;13:908436. [DOI: 10.3389/fimmu.2022.908436] [Reference Citation Analysis]
3 Del Conte A, De Carlo E, Bertoli E, Stanzione B, Revelant A, Bertola M, Spina M, Bearz A. Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. Int J Mol Sci 2022;23:6832. [PMID: 35743275 DOI: 10.3390/ijms23126832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]